The Anti-Mullerian Hormone Test Market size was estimated at USD 340.21 million in 2025 and expected to reach USD 381.30 million in 2026, at a CAGR of 11.83% to reach USD 744.42 million by 2032.

The anti-Müllerian hormone test, commonly known as the AMH test, has become a core tool in fertility diagnostics, ovarian reserve testing, IVF treatment planning, PCOS assessment, menopause-related evaluation, and fertility preservation counseling. Clinical demand is supported by the global burden of infertility, with the World Health Organization reporting that around 17.5% of adults experience infertility during their lifetime, with comparable prevalence across income settings. In practice, AMH testing is valued because it can add prognostic insight into expected ovarian response, especially when interpreted alongside age, antral follicle count, reproductive history, and treatment goals. However, evidence-based positioning is essential: professional guidance emphasizes that AMH reflects oocyte quantity more than oocyte quality and should not be used alone as a general fertility prediction test for people not seeking fertility care.

The AMH testing landscape is shifting from isolated hormone measurement toward integrated reproductive decision support. In IVF and ICSI, evidence-based ovarian stimulation guidance recognizes AMH and antral follicle count as preferred markers for predicting high or poor ovarian response, supporting individualized stimulation protocols and risk mitigation. Clinical use is also broadening through the 2023 international PCOS guideline, which allows AMH to be used as an alternative to ultrasound for defining polycystic ovarian morphology in adults when used within diagnostic criteria. At the same time, the sector is becoming more quality- and compliance-driven: ISO 15189:2022 reinforces medical laboratory competence expectations, while the European in vitro diagnostic framework has raised requirements for quality, safety, reliability, and performance evaluation of IVDs.

Artificial intelligence is beginning to reshape AMH testing by turning static ovarian reserve results into dynamic clinical inputs for ovarian stimulation, follicular growth monitoring, dose adjustment, and patient stratification. Emerging evidence indicates that AI models in reproductive medicine can support prediction of ovarian response in IVF, with a recent systematic review reporting reliable performance for ovarian response forecasting. The cumulative impact is likely to be strongest where AMH values are combined with age, ultrasound findings, prior cycle response, body mass index, medication exposure, and laboratory quality indicators. Even so, AI adoption must remain clinically governed: algorithms require representative datasets, validation across ethnic and regional populations, transparent bias checks, and human oversight because AMH interpretation is context-sensitive and cannot independently determine fertility potential or treatment success.

Regional dynamics show a globally relevant but unevenly implemented AMH testing ecosystem. Asia-Pacific is shaped by high ART activity in countries with advanced registries, including Japan, where 602 facilities implemented ART treatment in 2022, and by expanding access frameworks in Australia, China, India, and South Korea. North America benefits from structured ART surveillance in the United States and national reporting in Canada, making AMH testing central to fertility workups and stimulation planning. Latin America’s regional ART registry supports increasingly standardized reproductive care, while Europe combines mature ART infrastructure with IVDR-driven compliance expectations. The Middle East shows concentrated fertility-care adoption in selected systems, whereas Africa faces the largest access and affordability constraints despite comparable infertility burden; this makes scalable, quality-assured AMH testing particularly relevant for equitable fertility diagnostics.

Across strategic country groups, AMH testing adoption reflects the intersection of fertility-care access, laboratory maturity, demographics, and regulation. ASEAN countries are positioned around urban fertility centers, medical travel corridors, and rising reproductive health awareness, while GCC systems emphasize specialist-led fertility care supported by high private-sector participation and expanding women’s health services. The European Union is strongly influenced by IVDR, ISO-aligned laboratory quality, and evidence-based reproductive medicine guidance. BRICS countries combine large reproductive-age populations with varied access to fertility diagnostics, making standardization and affordability decisive. G7 countries generally have stronger laboratory infrastructure, ART reporting mechanisms, and clinical guideline adoption. NATO members overlap significantly with North American and European diagnostic networks, where AMH testing is embedded in reproductive endocrinology pathways but must remain aligned with patient counseling standards and data-protection expectations.

Country-level patterns reinforce the need for localized AMH testing strategies. In the United States, mandatory ART reporting supports data-driven fertility care, while Canada’s national ART registry strengthens outcome monitoring. Mexico and Brazil are important Latin American access points, with Brazil benefiting from regional registry participation. The United Kingdom, Germany, France, Italy, and Spain operate within mature European fertility ecosystems influenced by evidence-based guidance and IVD compliance, while Russia maintains significant specialist fertility capacity with distinct regulatory pathways. China, India, Japan, Australia, and South Korea are central to Asia-Pacific momentum: India’s ART Regulation Act requires clinic and bank registration through a national framework; Japan’s 2022 registry demonstrates broad facility participation; Australia and New Zealand maintain a comprehensive ART database; and South Korea reported 200,007 infertility treatment cycles in 2022 through its national system.

Industry leaders should position AMH testing as a clinically interpreted fertility diagnostic rather than a stand-alone fertility score. Priority actions include aligning claims with professional guidance, embedding AMH into multi-parameter ovarian reserve panels, harmonizing assay interpretation across laboratories, and providing clinician- and patient-facing education that clearly explains limits around natural fertility prediction. Laboratories and diagnostic providers should strengthen ISO 15189-based quality systems, ensure traceable reference intervals, validate assay performance across population groups, and integrate AMH results into secure digital workflows. Reproductive care providers should use AMH to personalize ovarian stimulation, identify potential poor or high responders, support PCOS evaluation in adults under guideline-based criteria, and guide fertility preservation discussions for patients facing gonadotoxic therapy.

The research methodology for this executive summary triangulates clinical guidelines, public health evidence, registry publications, regulatory references, and peer-reviewed literature. Core evidence inputs include infertility prevalence data, professional guidance on ovarian reserve testing, PCOS diagnostic recommendations, ART surveillance systems, laboratory quality standards, and IVD regulatory frameworks. The assessment excludes market estimation, market sizing, market share, and forecasting, focusing instead on verified adoption drivers, clinical utility, regulatory implications, and regional healthcare context. Findings are synthesized through a structured review of AMH testing use cases, including IVF stimulation planning, ovarian reserve assessment, PCOS evaluation, menopause-related assessment, fertility preservation, and laboratory governance. Emphasis is placed on data validity, source authority, clinical applicability, and avoidance of unsupported promotional claims.

The anti-Müllerian hormone test is moving deeper into reproductive health pathways as fertility care becomes more personalized, data-driven, and quality regulated. Its strongest value lies in predicting ovarian response and supporting treatment planning, especially in IVF, fertility preservation, and adult PCOS assessment when used within evidence-based criteria. The opportunity for stakeholders is not to overextend AMH as a universal fertility predictor, but to improve access to accurate testing, responsible interpretation, and integrated counseling. Regions with mature ART registries will continue refining clinical pathways, while underserved settings need affordable, reliable laboratory capacity. The next phase of AMH testing will be defined by standardization, AI-enabled decision support, regulatory readiness, and patient-centered communication grounded in clinical evidence.